Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma |
| |
| Institution: | 1. Department of Cancer Medicine, Gustave Roussy, Villejuif, France;2. Oncologia Medica Ospedale Bellaria Bologna, Bologna, Italy;3. Medical and Translational Oncology, Ospedale Santa Chiara di Terni, Terni, Italy;4. Department of Epidemiology, Gustave Roussy, Villejuif, France;5. Department of Radiology, Gustave Roussy, Villejuif, France;6. University of Paris-Saclay, Le Kremlin-Bicetre, France;1. Department of Urology, Faculty of Medicine, Sitki Kocman University, Muğla, Turkey;2. Department of Urology, Faculty of Medicine, Hacettepe University, Ankara, Turkey;3. Department of Urology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey;4. Department of Urology, Faculty of Medicine, Celal Bayar University, Manisa, Turkey;1. Department of Radiation Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Australia;2. Department of Radiation Oncology, Peter MacCallum Cancer Centre, Australia;3. Alfred Health Radiation Oncology Services, Australia;4. School of Clinical Medicine, University of Cambridge, UK;5. Department of Epidemiology and Preventive Medicine, Monash University, Australia;6. Cancer Epidemiology Division, Cancer Council Victoria, Australia;7. Centre for Epidemiology and Biostatistics, School of Population and Global Health, University of Melbourne, Australia;8. Precision Medicine, School of Clinical Sciences, Monash Health, Monash University, Australia;9. Central Clinical School, Monash University, Australia;1. Laboratory of Medical Investigation – LIM55, Urology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil;2. Instituto do Cancer do Estado de São Paulo – ICESP, São Paulo, Brazil;1. Department of Medical Oncology, CHRU Jean Minjoz, Besançon cedex, France;2. Université de Franche-Comté, Besançon cedex, France;3. Department of Medical Oncology, CHIC Quimper, Quimper, France;4. Department of Medical Oncology, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France;5. INSERM, Besançon cedex France;6. Methodology and Quality of Life in Oncology Unit, CHRU Jean Minjoz, Besançon cedex, France |
| |
| Abstract: | BackgroundCabozantinib, a potent multityrosine kinases inhibitor (TKI), has demonstrated overall survival (OS) benefit over everolimus in patients previously treated with VEGFR TKI for metastatic Renal Cell Carcinoma (mRCC). The efficacy of systemic treatments after cabozantinib failure has not been investigated.Materials and MethodsWe conducted a retrospective study on patients receiving systemic treatment after cabozantinib failure in heavily pretreated patient with mRCC. We assessed Time to Treatment Failure (TTF), OS and objective response rate (ORR).ResultsAmong 150 patients treated with cabozantinib in our institution, 56 (37.3%) received subsequent systemic therapy and were eligible for the analysis. IMDC prognostic group was good, intermediate and poor in 11 (19.6%), 24 (42.9%) and 11 (19.6%) patients, respectively. Cabozantinib was administered mainly as a second (41.1%), or third (33.9%) line treatment. axitinib or immune-checkpoint inhibitors were the subsequent treatment in 18 (34.8%) patients for each everolimus (n:16, 28.6%), other angiogenesis inhibitors (n:4, 7.1%) TTF and OS from subsequent systemic therapy after cabozantinib failure were 2.8 months (95%CI 1.9-3.7) and 7.7 months (95%CI 4.4-10.8), respectively. ORR was 8.7% and 2 patients with axitinib and 2 patients treated with Immune checkpoint inhibitors achieved a partial response.ConclusionOverall, activity of systemic therapies after cabozantinib was limited. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
